share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

Recursion Pharmaceuticals | 4：持股變動聲明-董事 Borgeson Blake
美股sec公告 ·  06/06 06:17
牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals, Inc. (RXRX) reported that Blake Borgeson, a key figure at the company, was granted 13,097 shares of Class A Common Stock on June 3, 2024. The transaction, which was completed on the same day, was a grant with a transaction price of $0.00 per share, indicating that the shares were likely awarded as part of a compensation package or incentive plan. Following this transaction, Borgeson's direct holdings in the company have increased to a total of 7,200,010 shares of Common Stock.
Recursion Pharmaceuticals, Inc. (RXRX) reported that Blake Borgeson, a key figure at the company, was granted 13,097 shares of Class A Common Stock on June 3, 2024. The transaction, which was completed on the same day, was a grant with a transaction price of $0.00 per share, indicating that the shares were likely awarded as part of a compensation package or incentive plan. Following this transaction, Borgeson's direct holdings in the company have increased to a total of 7,200,010 shares of Common Stock.
Recursion Pharmaceuticals, Inc.（RXRX）報告指，公司重要人物Blake Borgeson於2024年6月3日獲贈13,097股A類普通股。這筆交易在同一天完成，是一項價格為每股0.00美元的授予，表明這些股份很可能是作為補償計劃或激勵計劃的一部分而授予的。在此交易後，Borgeson在公司的直接持股已增加至共7,200,010股普通股。
Recursion Pharmaceuticals, Inc.（RXRX）報告指，公司重要人物Blake Borgeson於2024年6月3日獲贈13,097股A類普通股。這筆交易在同一天完成，是一項價格為每股0.00美元的授予，表明這些股份很可能是作為補償計劃或激勵計劃的一部分而授予的。在此交易後，Borgeson在公司的直接持股已增加至共7,200,010股普通股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。